CELEBRATING 16 YEARS AT CBSET... With broad scientific expertise in both drug and device development, Peter co-founded CBSET in 2006 and, as its CEO, has since led the way in establishing CBSET as the undisputed gold standard for preclinical science in the life sciences industry.
THREE THINGS YOU SHOULD KNOW ABOUT PETER M. MARKHAM
1: He is an internationally recognized life sciences industry leader.
Peter has broad scientific expertise in both drug and device development with specific expertise in metabolism, pharmacokinetics, bioanalytical chemistry, and the application of these scientific disciplines to the development of combination products. In 2019, he was the recipient of the Massachusetts Society for Medical Research (MSMR) Business Leader Award, and shares this distinguished honor with a select list of CEOs of large multi-nationals, leading biotechnology companies, and venture funds, including: Genzyme, Biogen, Novartis, Alkermes, Alnylam, CRL, Protein Sciences, MIT, Polaris, and Third Rock ventures.
Prior to co-founding CBSET, Peter served as General Manager of the Worcester/Southbridge division of Charles River Laboratories (CRL) where he had P&L responsibility for its largest multi-disciplinary preclinical business unit, which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets. Prior to CRL, he served as a senior executive and researcher specializing in drug metabolism, pharmacokinetics, and bioanalytical chemistry at companies including: Genzyme Transgenics, Primedica, BioDevelopment Laboratories, and Arthur D. Little Inc. He has authored or co-authored numerous original scientific publications.
2: He is a regulatory authority.
Peter is known internationally for his expertise in GLP regulatory compliance, setting and implementing corporate regulatory strategy and policies, and leading the development of regulatory strategies for novel technologies. His leadership has been recognized for creating high growth business units, developing novel services, expanding new markets through strategic implementation of and integration of advanced imaging and analytical technologies, and creating high- throughput laboratories.
Through partnering with the FDA, industry, academia, and the international physician community, CBSET has played a key role in advancing medical research, and these efforts have resulted in the clinical introduction and regulatory approval of countless devices and novel therapeutics for an active client base of 2000+ companies internationally.
3: He is revolutionizing translational research.
Under Peter’s leadership, CBSET has revolutionized how translational research is performed, creating the preeminent center for drug and device development, with a reputation for the highest quality and the ability to conduct complex and novel research programs under strict FDA Good Laboratory Practices (GLPs). “Peter has led CBSET to advance biomedical research by accelerating the evolution of technical and scientific acumen through collaborative projects in the medical device, pharmaceutical, and academic communities,” says Elazer R. Edelman, M.D., Ph.D., Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and senior attending cardiologist at Brigham and Women’s Hospital, Boston.
News and Publications
Scientific Reports: Morphometric analysis of the human common hepatic artery (CHA) reveals a rich and accessible target for sympathetic liver denervation
Biomaterials: Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients
Press Release: CBSET’s CEO Peter Markham honored as ‘2019 Biomedical Research Business Leader’ by Massachusetts Society for Medical Research (MSMR)
Translational Research: Splenic artery denervation: target micro-anatomy, feasibility, and early preclinical experience
Hypertension: Procedural and Anatomical Determinants of Multielectrode Renal Denervation Efficacy
Journal of Controlled Release: Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings
PLoS One: Sex differences in the outcomes of stent implantation in mini-swine model
Circulation: Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial
Journal of Controlled Release: Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis
Journal of Orthopaedic Research: Biocompatibility, bone healing, and safety evaluation in rabbits with an IlluminOss bone stabilization system
EuroIntervention: Ultra-hydrophilic stent platforms promote early vascular healing and minimise late tissue response: a potential alternative to second-generation drug-eluting stents
Ann Biomed Eng: Vascular Response to Experimental Stent Malapposition and Under-Expansion
J Biomed Mater Res B Appl Biomater: Evaluation of an intramedullary bone stabilization system using a light-curable monomer in sheep
EuroIntervention: Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity
Sci Transl Med: Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension
EuroIntervention: Particulates from hydrophilic-coated guiding sheaths embolise to the brain
Circ Cardiovasc Interv: Comparison of renal artery, soft tissue, and nerve damage after irrigated versus nonirrigated radiofrequency ablation
J Am Coll Cardiol: Innervation patterns may limit response to endovascular renal denervation
JACC Cardiovasc Interv: Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic Denervation
J Hypertens: Evaluation of renal nerve morphological changes and norepinephrine levels following treatment with novel bipolar radiofrequency delivery systems in a porcine model.